-

Exact Sciences to Participate in September Investor Conferences

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

  • Wells Fargo Healthcare Conference, Boston
    Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET
  • Baird Global Healthcare Conference, New York
    Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

Industry:

Exact Sciences Corp.

NASDAQ:EXAS
Release Versions
English

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

More News From Exact Sciences Corp.

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri...

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t...

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie...
Back to Newsroom